dibi
Selected indexed studies
- Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in Staphylococcus aureus. (Antibiotics (Basel), 2022) [PMID:36421286]
- Isthmocele: an overview of diagnosis and treatment. (Rev Assoc Med Bras (1992), 2019) [PMID:31166450]
- Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses. (Adv Pharm Bull, 2023) [PMID:37342371]
_Worker-drafted node — pending editorial review._
Connections
dibi helps
Sources
- Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in Staphylococcus aureus. (2022) pubmed
- Isthmocele: an overview of diagnosis and treatment. (2019) pubmed
- Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses. (2023) pubmed
- DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage. (2019) pubmed
- The Hydroxypyridinone Iron Chelator DIBI Reduces Bacterial Load and Inflammation in Experimental Lung Infection. (2024) pubmed
- Anti-inflammatory iron chelator, DIBI, reduces leukocyte-endothelial adhesion and clinical symptoms of LPS-induced interstitial cystitis in mice. (2021) pubmed
- The novel iron chelator, DIBI, attenuates inflammation and improves outcome in colon ascendens stent peritonitis-induced experimental sepsis. (2020) pubmed
- DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity. (2018) pubmed
- Anti-Inflammatory Effects of the Iron Chelator, DIBI, in Experimental Acute Lung Injury. (2022) pubmed
- Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus aureus, Is Anti-infective and Inhibitory for Mupirocin-Resistant Isolates. (2020) pubmed